Irish medical start-up Inflazone has raised €15m funding to help it explore proposed new treatments for chronic inflammatory diseases.
Inflazone is developing treatments which look to regulate the body's own immune response to help sufferers of conditions driven by chronic inflammation.
These diseases include Parkinsons, Asthma, Alzheimers and Arthritis.
The company was co-founded by Professor Matt Cooper from the University of Queensland in Australia and Trinity College Dublin's Professor Luke O'Neill.
Commenting on the launch of Inflazome, Professor O' Neill said "Animal models and clinical data suggests there is tremendous opportunity to stop the cycle of chronic inflammation in a range of diseases.
"We believe that targeting the inflammasome has tremendous potential for a wide range of inflammatory diseases where current treatments are ineffective."
The funding comes from venture capital firms Novartis Venture Funds and Fountain Healthcare Partners.
